Development of Potent Inhibitors of Receptor Tyrosine Kinases by Ligand-Based Drug Design and Target-Biased Phenotypic Screening-Reference-Cited by-同舟云学术

Development of Potent Inhibitors of Receptor Tyrosine Kinases by Ligand-Based Drug Design and Target-Biased Phenotypic Screening

Published:2018-02-21 Issue:5 Volume:61 Page:2104-2110
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Myers Samuel H.¹,Temps Carolin¹,Houston Douglas R.²,Brunton Valerie G.¹,Unciti-Broceta Asier¹^ORCID

Affiliation:

1. Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, U.K.

2. Institute of Quantitative Biology, Biochemistry and Biotechnology, University of Edinburgh, Edinburgh EH9 3BF, U.K.

Funder

College of Medicine and Veterinary Medicine, University of Edinburgh

Cancer Research UK

ScottishPower

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

http://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.7b01605

Reference25 articles.

1. The $2.6 Billion Pill — Methodologic and Policy Considerations

2. Innovation in the pharmaceutical industry: New estimates of R&D costs

3. Can the pharmaceutical industry reduce attrition rates?

4. Modern Phenotypic Drug Discovery Is a Viable, Neoclassic Pharma Strategy

5. Targeting the cancer kinome through polypharmacology

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent discovery and development of AXL inhibitors as antitumor agents;European Journal of Medicinal Chemistry;2024-06

2. Design, synthesis, and evaluation of new benzimidazole‏ ‏‎thiourea ‎derivatives as antitumor agents;Archiv der Pharmazie;2023-08-21

3. Discovery of pyrazolopyrimidines that selectively inhibit CSF-1R kinase by iterative design, synthesis and screening against glioblastoma cells;RSC Medicinal Chemistry;2023

4. Bicyclic 5–6 Systems: Other Four Heteroatoms 2:2;Comprehensive Heterocyclic Chemistry IV;2022

5. An overview of kinase downregulators and recent advances in discovery approaches;Signal Transduction and Targeted Therapy;2021-12